Efficacy, safety and recommendations for use of tetanus, diphtheria vaccines and whooping cough (DPT) in children exposed and infected by viruses human immunodeficiency (HIV)

Autor: Aramburu, Adolfo

Publikováno v: Instituto Nacional de Salud
Repositorio Institucional-INS
INS-Institucional
instacron:INS

Describir la evidencia científica sobre la eficacia, seguridad y recomendaciones de uso de vacunas contra tétanos, difteria y tos ferina (DPT) en niños expuestos e infectados con VIH.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::e9c9554077df209c5251fa9d84aa9f22
https://repositorio.ins.gob.pe/handle/INS/1453

Efectividad de la vacuna acelular antipertussis en adolescentes: una revisión sistemática

Autor: Niño Ruiz, Carmen Judith

Publikováno v: 1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385-400.
2. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-87.
3. Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S. Diagnosis and management of pertussis. Cmaj. 2005;172(4):509-15.
4. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(1):13-5.
5. Wheeler JG, Simmons AL. Pertussis update. Pediatr Infect Dis J. 2005;24(9):829-30.
6. Tan T. Summary: epidemiology of pertussis. Pediatr Infect Dis J. 2005;24(5 Suppl):S35-8.
7. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr. 2008;167(2):133-9.
8. Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J. 2005;24(8):721-8.
9. Edwards K, Freeman DM. Adolescent and adult pertussis: disease burden and prevention. Curr Opin Pediatr. 2006;18(1):77-80.
11. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004;190(3):535-44.
12. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555-63.
13. Galanis E, King AS, Varughese P, Halperin SA. Changing epidemiology and emerging risk groups for pertussis. Cmaj. 2006;174(4):451-2.
14. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24(5 Suppl):S25-34.
15. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367(9526):1926-36.
16. Warfel JM, Beren J, Merkel TJ. Airborne transmission of Bordetella pertussis. J Infect Dis 2012; 206:902.
17. Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.
18. Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.
19. Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.
20. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32(12):1691-7.
21. Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185(10):1448-53.
22. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22(1):22-7.
23. Guiso N, Wirsing von Konig CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine. 29. Netherlands: Copyright A© 2010. Published by Elsevier Ltd.. All rights reserved.; 2011. p. 1115-21.
24. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 1978; 132:371.
25. Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Pertussis in Other Countries. http://www.cdc.gov/pertussis/countries.html.
26. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-61.
27. Dworkin MS. Adults are whooping, but are internists listening? Ann Intern Med 2005; 142:832.
28. Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.
29. Wendelboe AM, Hudgens MG, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol. 2007;4:15.
30. Cherry JD, Heininger U. Pertussis. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia, PA: W. B. Saunders; 2003.
31. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985.
32. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293.
33. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238.
34. Tablas_2013_A_SEM 52. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co /lineas-de-accion/Subdireccion-Vigilancia /sivigila /Paginas /vigilancia-rutinaria.aspx
35. Informe del evento de la vigilancia de tosferina, hasta periodo epidemiologico cuatro (IV) del año 2014. Version: 01. Extraido el 6 de junio de 2014 desde http://www.ins.gov.co:81/lineas-de-accion/Subdireccion-Vigilancia/Informe %20de%20Evento%20Epidemiolgico/TOSFERINA%20Periodo%20IV%202014. pdf
36. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100(6):E10.
37. Nieves DJ, Singh J, Ashouri N, et al. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic. J Pediatr 2011; 159:1044.
38. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.
39. Tozzi AE, Ravà L, Ciofi degli Atti ML, et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003; 112:1069.
40. Couzigou C, Flahault A. Is pertussis being considered as a cause of persistent cough among adults? Eur J Epidemiol 2003; 18:1013.
41. Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006; 333:174.
42. Laboratory manual for the diagnosis of whooping cough caused by Bordetella pertussis/ Bordetella parapertussis. Geneva, World Health Organization, 2007 (WHO/ IPV/04.14). Also available from http://www.who.int/immunization/documents/ WHO_IVB_04.14/en/index.html.)
43. Riffelmann M, Wirsing von Konig CH, Caro V, Guiso N. Nucleic Acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol. 2005;43(10):4925-9.
44. Njamkepo E et al. Thirty-five years’ experience with the whole-cell pertussis vaccine in France:vaccine strains analysis and immunogenicity. Vaccine, 2002, 20:1290–1294.
45. Lai FY, Thoon KC, Ang LW, Tey SH, Heng D, Cutter JL, et al. Comparative seroepidemiology of pertussis, diphtheria and poliovirus antibodies in Singapore: waning pertussis immunity in a highly immunized population and the need for adolescent booster doses. Vaccine. 2012;30(24):3566-71.
46. Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, et al. Safe and effective booster immunization using DtaP in teenagers. Vaccine. 2010;28(48):7626-33.
47. Camenga DR, Kyanko K, Stepczynski J, Flaherty-Hewitt M, Curry L, Sewell D, et al. Increasing adult Tdap vaccination rates by vaccinating infant caregivers in the pediatric office. Acad Pediatr. 2012;12(1):20-5.
48. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(6 Suppl):S104-8.
49. de Carvalho AP, Pereira EM. Acellular pertussis vaccine for adolescents. J Pediatr (Rio J). 2006;82(3 Suppl):S15-24.
50. Singh M, Lingappan K. Whooping cough: the current scene. Chest. 2006;130(5):1547-53.
51. Griffiths AH. Permanenent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine 1989;7:199–210.
52. Protocolo de vigilancia en salud publica Tosferina, Version 03. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia /sivigila / Protocolos%20SIVIGILA/PRO%20Tos%20ferina.pdf
53. Cohen S, Black A, Ross A, Mandel ED. Updated treatment and prevention guidelines for pertussis. Jaapa. 2014;27(1):19-25, quiz 6.
54. Pickering LK, Baker CJ, Freed GL, Gall SA, Grogg SE, Poland GA, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(6):817-40.
55. Cherry JD. Pertussis vaccines for adolescents and adults. Pediatrics. 2005;116(3):755-6.
56. Halperin SA. Pertussis–a disease and vaccine for all ages. N Engl J Med. 353. United States2005. P. 1615-7.
57. Akinsanya-Beysolow I, Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:108.
58. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010; 50:1339.
59. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine. 2012;30(35):5179-90.
60. Food and Drug Administration. Product approval information-licensing action, package insert: BOOSTRIX®. Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed. GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005.
61. Food and Drug Administration. Product approval information-licensing action, package insert: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed ADACELTM. Sanofi celula. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.
62. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117(3):965-78.
63. Wilson TR. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J Pediatr Health Care. 2006;20(4):229-37.
64. Lineamiento Estratégico para la Introducción de la Vacuna TdaP (Tétanos-Difteria-Tos ferina acelular) en el Esquema del Programa Ampliado de Inmunizaciones –PAI Para Mujeres Gestantes de las cohortes 2013 y 2014. Extraido el 6 de Junio de 2014 desde http://www.minsalud.gov.co /Documentos %20y%20Publicaciones/Lineamiento%20Estrat%C3%A9gico%20para%20la%20Introducci%C3%B3n%20de%20la%20Vacuna%20TdaP.pdf
65. Protocolo Tos Ferina 2013. Extraido el 6 de Junio de 2014 desde http://www.ins.gov.co/Noticias/Memorias%20Reunin%20Nacional%20de%20Vigilancia%20y%20Control%20e/2-8-tosferina.pdf
66. Pichichero ME, Casey JR, Francis AB, Marsocci SM, Murphy M, Hoeger W, et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phila). 2006;45(7):613-20.
67. Tran Minh NN, He Q, Ramalho A, Kaufhold A, Viljanen MK, Arvilommi H, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999;104(6):e70.
68. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. Jama. 2005;293(24):3003-11.
69. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23(29):3829-35.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

La incidencia de la tosferina ha mostrado un incremento en los últimos años; afectando predominantemente a los niños menores de 1 año, adolescentes y adultos. En el 2005 el Comité Asesor de Prácticas en Inmunización (ACIP) recomendó administr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea2c43807b4c3d0f5f54b36838178dd9
http://repository.urosario.edu.co/handle/10336/6363